These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15562199)

  • 21. Insulin dose-response curves for stimulation of splanchnic glucose uptake and suppression of endogenous glucose production differ in nondiabetic humans and are abnormal in people with type 2 diabetes.
    Basu R; Basu A; Johnson CM; Schwenk WF; Rizza RA
    Diabetes; 2004 Aug; 53(8):2042-50. PubMed ID: 15277384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic insulin sensitivity in healthy and prediabetic subjects: from a dual- to a single-tracer oral minimal model.
    Visentin R; Dalla Man C; Basu R; Basu A; Rizza RA; Cobelli C
    Am J Physiol Endocrinol Metab; 2015 Jul; 309(2):E161-7. PubMed ID: 25991649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects.
    Pratipanawatr T; Pratipanawatr W; Rosen C; Berria R; Bajaj M; Cusi K; Mandarino L; Kashyap S; Belfort R; DeFronzo RA
    Am J Physiol Endocrinol Metab; 2002 Jun; 282(6):E1360-8. PubMed ID: 12006367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes.
    Linn T; Fischer B; Soydan N; Eckhard M; Ehl J; Kunz C; Bretzel RG
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3839-46. PubMed ID: 18611975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
    Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
    Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
    Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
    Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects.
    Rave K; Heise T; Weyer C; Herrnberger J; Bender R; Hirschberger S; Heinemann L
    Diabet Med; 1998 Sep; 15(9):747-51. PubMed ID: 9737803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.
    Mudaliar S; Henry RR; Ciaraldi TP; Armstrong DA; Burke PM; Pettus JH; Garhyan P; Choi SL; Knadler MP; Lam EC; Prince MJ; Bose N; Porksen NK; Sinha VP; Linnebjerg H; Jacober SJ
    Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():17-24. PubMed ID: 27723226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repeatability and reproducibility of the hyperinsulinemic-euglycemic clamp and the tracer dilution technique in a controlled inpatient setting.
    Le DS; Brookshire T; Krakoff J; Bunt JC
    Metabolism; 2009 Mar; 58(3):304-10. PubMed ID: 19217443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes.
    Heinemann L; Nosek L; Flacke F; Albus K; Krasner A; Pichotta P; Heise T; Steiner S
    Diabetes Obes Metab; 2012 Mar; 14(3):222-7. PubMed ID: 21981286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal and metabolic effects of insulin lispro in type 2 diabetic subjects with overt nephropathy.
    Ruggenenti P; Flores C; Aros C; Ene-Iordache B; Trevisan R; Ottomano C; Remuzzi G
    Diabetes Care; 2003 Feb; 26(2):502-9. PubMed ID: 12547889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients.
    Bajaj M; Suraamornkul S; Hardies LJ; Pratipanawatr T; DeFronzo RA
    Int J Obes Relat Metab Disord; 2004 Jun; 28(6):783-9. PubMed ID: 15024400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
    Bajaj M; Suraamornkul S; Romanelli A; Cline GW; Mandarino LJ; Shulman GI; DeFronzo RA
    Diabetes; 2005 Nov; 54(11):3148-53. PubMed ID: 16249438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of intranasal insulin on endogenous glucose production in insulin-resistant men.
    Xiao C; Dash S; Stahel P; Lewis GF
    Diabetes Obes Metab; 2018 Jul; 20(7):1751-1754. PubMed ID: 29536605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-response relationship of oral insulin spray in healthy subjects.
    Cernea S; Kidron M; Wohlgelernter J; Modi P; Raz I
    Diabetes Care; 2005 Jun; 28(6):1353-7. PubMed ID: 15920051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin.
    ter Braak EW; Woodworth JR; Bianchi R; Cerimele B; Erkelens DW; Thijssen JH; Kurtz D
    Diabetes Care; 1996 Dec; 19(12):1437-40. PubMed ID: 8941480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Counterregulatory hormone responses and symptoms during hypoglycaemia induced by porcine, human regular insulin, and Lys(B28), Pro(B29) human insulin analogue (insulin Lispro) in healthy male volunteers.
    Jacobs MA; Salobir B; Popp-Snijders C; Ader H; Heine RJ
    Diabet Med; 1997 Mar; 14(3):248-57. PubMed ID: 9088775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different sensitivity of glucose and amino acid metabolism to insulin in NIDDM.
    Luzi L; Petrides AS; De Fronzo RA
    Diabetes; 1993 Dec; 42(12):1868-77. PubMed ID: 8243833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Oct; 21(10):1707-13. PubMed ID: 9773735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.